Ostarine is the closest SARM to getting approved in medicine and is also now in section II clinical trials. Like SARMs generally speaking, MK-2866 targets androgen receptors on a selective foundation and avoids generating the forms of hazardous side effects associated with substances like testosterone, human growth hormone, or anabolic https://collinsc220rix8.idblogz.com/profile